Leif R. Nelson
New technologies delivered to your inbox Subscribe
2015-347 – Mayo Clinic has developed compositions and methods for detecting soluble PD-L1
2013-237 – Bim is a biomarker for PD-1 and PD-L1 therapies.
Methods of Treating Cancer by Using PD1 and PD-L1 inhibitors by Using Soluble PD-L1 Levels as a Biomarker
2008-042 – Mayo Clinic has patent rights claiming methods of using PD1 or PD-L1 antibodies to treat cancer by using soluble PD-L1 levels in the serum as a biomarker.
2003-132 – Mayo Clinic has patent rights claiming methods of detecting the autoantibody associated with NMO.
2004-239 – Mayo Clinic has patent rights claiming the use of PD1 and PD-L1 antibodies to treat cancer. The patent rights also include diagnostic and prognostic claims.
2002-064 – Mayo Clinic has patent rights broadly claiming the use of PD-L1 antibodies to treat cancer.
1999-098 – Mayo Clinic has patent rights broadly claiming PD-L1 antibodies along with other PD-L1 related fundamental patent claims.
2014-207 – Mayo Clinic has discovered a therapeutic pathway to target PD-L1 (a.k.a. B7-H1) positive tumors. Inhibition of DNA-PKcs function restores the sensitivity of PD-L1 positive tumors to chemotherapy by two fold.
Aquaporin-4-Binding Autoantibodies in Patients with Neuromyelitis Optica Impair Glutamate Transport by Down-Regulating EAAT2
2008-303 – Materials and Methods for Treating Neuromyelitis Optics (NMO) Methods for treating NMO are claimed including the use of glulamate receptor antagonists and/or compounds that inhibit complement.
2006-290 – Technology Description Expression of B7-H3 on the cell surface of tumor cells and tumor-associated vasculature is greatly increased in prostate and renal cancers. B7-H3 is predictive of disease progression and poor survival and is a therapeutic target for tumor cells and tumor-associated vessels by antibody directed cytotoxicity. Application B7-H3 may be a useful prognostic marker for... Read More
2006-018 – Technology Description B7-H4 is a cell surface protein whose expression on tumor cells and tumor-associated vasculature is greatly increased in renal cancers. B7-H4 expression levels on renal tumors have been shown to be a predictor of tumor aggressiveness and to increase mortality rates. B7-H4 is highly expressed on tumors and tumor-associated vasculature but not on normal tissues and... Read More
2002-039 – Technology Description T cell-mediated immune responses are often harmful in transplant patients and patients with autoimmune disease. Currents treatments to suppress T cell-mediated immune responses include a number of immunosuppressive and anti-inflammatory therapies. A novel means of suppressing this immune response has been developed that utilizes mutant forms of a protein normally... Read More
1998-066 – The Mayo Clinic is developing and testing a synbiotic (composition of synergistic probiotic organisms and a prebiotic) for clinical indications (Croh'n’s, IBD, immunocompromised patients, patients undrgoing chemo or radiation therapy, patients infected with antibiotic resistant organisms. THe synbiotic has proven to be very effective in several animal trials including animals that were... Read More